Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Michael Paul, PhD to its Board of Directors, effective March 18, 2024. With decades of experience in life sciences innovation, capital formation, and management, Dr. Paul brings industry insight and visionary leadership to accelerate Seek Labs’ growth, strategic initiatives, and research.

Dr. Paul has made significant contributions to the life sciences industry through groundbreaking innovation and strategic leadership. His deep expertise in navigating the complexities of the industry, coupled with a proven track record of raising capital, driving growth, and transformation, makes Dr. Paul an invaluable addition to the Seek Labs board.

"We are honored to be joined by Dr. Michael Paul on our Board,” said Jared Bauer, CEO. "Michael Paul has extensive experience in our industry, and his visionary leadership in life sciences innovation and management will bring fresh perspectives and insights as we continue to foster innovation and technological advancement, as well as develop our product commercialization strategy. We look forward to leveraging Michael’s expertise to propel Seek Labs forward."

Dr. Paul is CEO, President, and Director of MARAbio, a precision immunology biotechnology company that is commercializing groundbreaking technologies to detect Maternal Autoantibody Related Autism (MARA), an autoimmune subtype of autism associated with more severe forms of the condition. Prior to his appointment as MARAbio’s CEO, Dr. Paul co-founded Lineagen, Inc. in 2006, where he served as President, CEO, and Director from the company’s start up to commercial growth and through its strategic acquisition in 2020. He earned a BA from Colby College and went on to earn a PhD in Molecular Biology and Biochemistry from the University of Utah.

“I am excited to join the Board of Directors of Seek Labs, a company that is setting the bar for diagnostic and pharmaceutical innovation,” said Dr. Paul. “I am eager to collaborate with the board and management team to build on the great foundation Seek has laid and add my insights to accelerate Seek Labs’ impact in the life sciences industry and help the company accomplish its compelling strategic vision and mission to improve global health.”

Dr. Paul has been recognized as one of Utah’s leading entrepreneurs, for which he was appointed to the Utah Technology Industry Commission by former Governor Michael O. Leavitt. He has also served as Vice Chairman for the Utah Technology Council. Dr. Paul was a finalist for E&Y’s 2018 Entrepreneur of the Year award and was named a “Utah 100 Winner” by MountainWest Capital Network.

About Seek Labs

Seek Labs is a company united by a vision to advance scientific discovery and universal solutions. Seek Labs strives to innovate healthcare solutions that bridge gaps between patients, providers, and treatments. Seek Labs is united by the passion of our founders and their shared beliefs that healthcare solutions should empower individuals and serve their specific needs. Today—after years of experimentation, failure, and breakthrough— Seek Labs is developing new solutions for point-of-care diagnostics and CRISPR-based pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases.

Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and patients.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240319675076/en/